133 related articles for article (PubMed ID: 25130993)
1. Role of bisphosphonates in non-metastatic prostate cancer.
Saad F
Lancet Oncol; 2014 Sep; 15(10):1041-2. PubMed ID: 25130993
[No Abstract] [Full Text] [Related]
2. Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Urol; 2014 Nov; 11(11):599. PubMed ID: 25201618
[No Abstract] [Full Text] [Related]
3. Prostate cancer: Androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Clin Oncol; 2014 Oct; 11(10):559. PubMed ID: 25200412
[No Abstract] [Full Text] [Related]
4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
5. The opportunity cost of androgen suppression in locally advanced prostate cancer.
Gray PJ; Efstathiou JA; Shipley WU
Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
[No Abstract] [Full Text] [Related]
6. Harms versus benefits with duration of androgen suppression.
Nguyen PL
Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
[No Abstract] [Full Text] [Related]
7. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
9. The role of bisphosphonates in the treatment of prostate cancer.
Parker CC
BJU Int; 2005 May; 95(7):935-8. PubMed ID: 15839907
[No Abstract] [Full Text] [Related]
10. [Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
Expert Group on the Diagnosis and Treatment of Bone Metastasis from Prostate Cancer
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):396-8. PubMed ID: 20723442
[No Abstract] [Full Text] [Related]
11. Editorial comment.
Tan WW
Urology; 2010 May; 75(5):1143. PubMed ID: 20451736
[No Abstract] [Full Text] [Related]
12. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Pitts WR
J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
[No Abstract] [Full Text] [Related]
13. Relapsing Prostate Cancer: Castrate or Cure?
Tharmalingam H; Choudhury A
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1095-1096. PubMed ID: 29722651
[No Abstract] [Full Text] [Related]
14. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
[No Abstract] [Full Text] [Related]
16. Management of androgen-independent prostate cancer.
Diaz M; Patterson SG
Cancer Control; 2004; 11(6):364-73. PubMed ID: 15625524
[TBL] [Abstract][Full Text] [Related]
17. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
18. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
19. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
Polascik TJ
Prostate Cancer Prostatic Dis; 2008; 11(1):13-9. PubMed ID: 17923854
[TBL] [Abstract][Full Text] [Related]
20. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]